Published June 15, 2021
| Version v1
Patent
Open
Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
- 1. University of Chicago
Contributors
Patent applicant:
Description
The invention provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.
Files
US11034962.pdf
Files
(4.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:2920cdac0318a97093b2313ebc097ccd
|
4.7 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 11034962 B2
- Patent application number
- US 201916450760 A
- Other
- oai:uchicago.tind.io:7358
Dates
- Patent filed
-
2019-06-24